Kuehn Law Investigates Fractyl Health Over Alleged Misconduct

The legal inquiry stems from a federal securities lawsuit alleging that Fractyl Health obscured significant flaws in its clinical study process. According to the complaint, the company misrepresented the efficacy of Revita—an outpatient treatment for duodenal dysfunction—while failing to disclose that operational issues at study sites may have compromised the integrity of its reported results. These omissions allegedly led to an inflated assessment of the therapy's regulatory and commercial prospects.

Kuehn Law is currently vetting shareholders who held GUTS stock prior to the January 2025 threshold. Those interested in participating in the potential litigation are instructed to contact Sophia Anne Silayan at ssilayan@kuehnlaw.com or by phone at (833) 672-0814. The firm operates on a contingency basis, covering all case costs for its clients.